Medigene acquires Trianta Immunotherapies

27 January 2014

Germany’s Medigene (MDG: DE) this morning revealed that it has acquired 100% of the shares of the Munich-based company Trianta Immunotherapies GmbH (Trianta), a spin-off of the Helmholtz Zentrum Munchen.

Previous Trianta shareholders will receive 1,017,811 newly issued Medigene shares worth around 4 million euros ($5.5 million) and potential incremental payments in further Medigene shares or in cash of up to a maximum total of 5.875 million euros on the achievement of future milestones.

Trianta is developing three highly innovative and complementary immunotherapy platforms with programs in clinical development to treat various tumor types. Trianta’s proprietary technologies will enhance Medigene’s advanced pipeline with cutting-edge therapies, the company stated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK